Checkpoint inhibitors and gastrointestinal immune-related adverse events
Simon Pernot(Sciences Po Bordeaux), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Toulsie Ramtohul(Université Paris Sciences et Lettres)
Cited by 40
Related Papers
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
|Journal of Clinical Oncology|2020|222
Colorectal cancer and immunity: What we know and perspectives
|World Journal of Gastroenterology|2014|132
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
|Breast Cancer Research|2020|125